A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs HS-10374 (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
- 08 Nov 2024 New trial record